Dermatol. praxi. 2016;10(2):66-69 | DOI: 10.36290/der.2016.016

Use of omalizumab in dermatology

MUDr. Iva Karlová
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Omalizumab is a humanized monoclonal anti-IgE antibody. It binds to the circulating IgE to form a biologically inert molecule that inhibits further interaction between IgE and FcεR1 receptor on mast cells and basophils. Omalizumab affects the activity of mast cells that become more stable with this treatment. Their degranulation threshold increases, resulting in the release of vasoactive mediators. Omalizumab was primarily indicated for the treatment of patients with asthma; this indication has been extended to include chronic spontaneous urticaria. The safety and efficacy of omalizumab has been demonstrated in three randomized, placebo-controlled studies in patients with chronic spontaneous urticaria.

Keywords: omalizumab, chronic spontaneous urticaria, autoreactivity

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karlová I. Use of omalizumab in dermatology. Dermatol. praxi. 2016;10(2):66-69. doi: 10.36290/der.2016.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://remedia.cz/Clanky/Lekove-profily/Omalizumab/6-I-j5.magarticle.aspx.
    2. Ferrer M, Sastre J, Jáuregui I, et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol 2011; 21(3): p. 34-39.
    3. Benáková N. Současné praktické postupy pro vyšetřování a léčbu chronické urtikárie.Čes-slov Derm, 2015; 90(5): p. 198-212.
    4. Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129: p. 1307-1313. Go to original source... Go to PubMed...
    5. Maurer M, Grabbe J. Urticara: Its History - based diagnosis and etiologically oriented treatment. Deutsches Ärzteblatt International 2008; 105(25): p. 458-466. Go to original source... Go to PubMed...
    6. Chang TW, Chen C, Lin Ch-J, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. A Allergy Clin. Immunol. 2015; 136(2): p. 337-342. Go to original source... Go to PubMed...
    7. Kaplan A. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 2012; 4(6): p. 326-331. Go to original source... Go to PubMed...
    8. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and manegement of urticaria: the2013 revision un update. Allergy 2014; 69: p. 868-887. Go to original source... Go to PubMed...
    9. Savic S, Marsland A, McKay D, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy, Asthma & Clinical Immunology 2015; 11: 21. Go to original source... Go to PubMed...
    10. http://www.sukl.cz/modules/medication/detail.php?code=0149028&tab=prices.
    11. Kaplan A, Ferrer M, Bernstein J A, et al. Timing and duration of omalizumab response in patients with chronic idoiopatic/spontaneous urticaria. J Allergy Clin Immunol 2015. Go to PubMed...
    12. Labrador-Horrillo M, Valero A, Velasco M, et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.